Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Global Blood Therapeutics, Inc. GBT
$68.49
На 18:00, 12 мая 2023
-11.84%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
0.00000000
-
week52high
73.02
-
week52low
21.65
-
Revenue
194749000
-
P/E TTM
-18
-
Beta
0.46344300
-
EPS
-4.86400000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 ноя 2022 г. в 00:13
Описание компании
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cantor Fitzgerald | Neutral | Overweight | 19 авг 2022 г. |
| Wells Fargo | Equal-Weight | Overweight | 09 авг 2022 г. |
| SVB Leerink | Market Perform | Outperform | 09 авг 2022 г. |
| RBC Capital | Sector Perform | Outperform | 09 авг 2022 г. |
| Cantor Fitzgerald | Neutral | Overweight | 09 авг 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| SUVARI TRICIA BORGA | D | 0 | 28628 | 05 окт 2022 г. |
| SUVARI TRICIA BORGA | D | 0 | 28628 | 05 окт 2022 г. |
| SUVARI TRICIA BORGA | D | 0 | 28628 | 05 окт 2022 г. |
| Farrow Jeffrey S | D | 0 | 28628 | 05 окт 2022 г. |
| Farrow Jeffrey S | D | 0 | 28628 | 05 окт 2022 г. |
| Farrow Jeffrey S | D | 0 | 28628 | 05 окт 2022 г. |
| Krehlik Carrie | D | 0 | 28628 | 05 окт 2022 г. |
| Krehlik Carrie | D | 0 | 28628 | 05 окт 2022 г. |
| Krehlik Carrie | D | 0 | 28628 | 05 окт 2022 г. |
| Habibizad Nazila | D | 0 | 28628 | 05 окт 2022 г. |
Новостная лента
Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals
Seeking Alpha
16 сент 2022 г. в 12:41
After a slow first half, merger and acquisition deals are heating up for the remainder of 2022. In the efforts to boost its presence in rare hematology, Pfizer recently announced it is acquiring Global Blood Therapeutics for $5.4B.
Get ready for more merger mania in pharma sector the rest of the year
Market Watch
09 авг 2022 г. в 14:43
Pfizer Inc.'s PFE, +0.24% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, +0.02% is the latest sign that cash-flush drug makers are ready to jump back into dealmaking.
Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings
Zacks Investment Research
09 авг 2022 г. в 12:47
Global Blood (GBT) is set to be acquired by Pfizer for around $5.4 billion. The company missed estimates for earnings while beating the same for revenues in the second quarter of 2022.
Pfizer is acquiring Global Blood Therapeutics
Invezz
09 авг 2022 г. в 11:49
Pfizer Inc (NYSE: PFE) has executed a definitive merger agreement with Global Blood Therapeutics Inc (NASDAQ: GBT), whereby Pfizer will acquire the biopharmaceutical corporation dedicated to the delivery, development and discovery of life-changing medical treatment, Global Blood Therapeutics, for $5.4 billion, representing $68.50 per GBT share.
Pfizer to buy Global Blood Therapeutics for US$5.4bn
Proactive Investors
09 авг 2022 г. в 06:18
Pfizer Inc (NYSE:PFE) is to pay US$5.4bn in cash to acquire sickle cell disease drugmaker Global Blood Therapeutics, Inc (NASDAQ:GBT) (GBT) as the pharma major looks to leverage the booming revenue from its Covid-19 vaccine and treatment. Pfizer will pay US$68.50 per GBT share, which represents a 7.3% premium over Friday's closing price and nearly 43% over Thursday's closing price.